PR89694

LONDON, May 25, 2021 /PRNewswire=KYODO JBN/ --

Lifebit's precision medicine software will power Hong Kong's development of

genomic medicine by supporting the Hong Kong Genome Institute to implement the

first large-scale genome sequencing initiative, the Hong Kong Genome Project.

The Project will empower medical professionals and researchers to leverage up

to 50,000 whole genomes to achieve faster diagnosis, more precise and

personalised treatments and perform disease surveillance.

The leader in precision medicine technology, Lifebit Biotech Ltd, today

announced it has been awarded a four-year contract by Hong Kong Genome

Institute (HKGI) to support its implementation of the first large-scale genome

sequencing initiative in Hong Kong.

Lifebit offers federated solutions for leading precision medicine initiatives.

In 2020, Lifebit and Genomics England launched a Trusted Research Environment [

https://www.genomicsengland.co.uk/research-environment-covid-19-lifebit-aws/

]which provides top pharma companies, researchers and clinicians secure and

full-fledged analysis access to cancer and rare disease clinico-genomic data.

Funded by the Hong Kong SAR Government [

https://www.info.gov.hk/gia/general/202005/14/P2020051400636.htm ], HKGI is

tasked to take forward the implementation of the Project with the view of

serving as a catalyst to establish a genome database of local population,

testing infrastructure and talent pool in Hong Kong. All of these will greatly

facilitate the clinical application of genomic medicine and scientific

research, and benefit patients and their families. To support HKGI and the

Project, Lifebit will deploy a highly scalable cloud and HPC infrastructure to

transform raw sequencing data into clinical diagnosis and research insights in

as little as 3 hours.

Thorben Seeger, Lifebit VP Commercial, said:

"Precision medicine requires vast amounts of data to be analysed and we believe

federated analysis will play a key role in powering the Project for HKGI. This

federated approach is tremendously increasing researchers' access to diverse

population genomics data worldwide, without putting sensitive patient data at

risk, as the data will always remain secure in each initiative's own

environment."

For the full release, click here [

https://blog.lifebit.ai/2021/05/25/hong-kongs-genome-lifebit/ ].

About Lifebit

To cure diseases, researchers need to access and use as much biomedical data as

possible, which are often inaccessible and unusable. Lifebit's patented

federated technology securely unlocks access to data-generating insights and

delivers more precise drugs faster. From providing Trusted Research

Environments for national precision medicine programmes to enabling

pharmaceutical companies to discover new drug targets, Lifebit empowers

customers across the public and private sectors to transform how they use

sensitive biomedical data.

Photo - https://mma.prnewswire.com/media/1516831/Lifebit_HK_Genome_Project.jpg

Source: Lifebit Internal / Commercial Team